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Objectives The aim of this study was to evaluate the efficacy and safety of mipomersen in hypercholesterolemic subjects
taking stable statin therapy.
Background Mipomersen is an apolipoprotein (apo) B synthesis inhibitor that has demonstrated significant reductions in
apo B and low-density lipoprotein (LDL) cholesterol in Phase 1 clinical trials in healthy volunteers.
Methods A randomized, placebo-controlled, dose-escalation Phase 2 study was designed to evaluate the effects of mi-
pomersen in hypercholesterolemic subjects taking stable statin therapy. Seventy-four subjects were enrolled se-
quentially into 1 of 6 dose cohorts at a 4:1 (active/placebo) ratio. Subjects received 7 doses of 30 to 400 mg
over 5 weeks in the first 5 cohorts and 15 doses of 200 mg over 13 weeks in the sixth cohort. Pre-specified end
points included percentage change from baseline in apo B and LDL cholesterol. Safety was assessed with labo-
ratory test results and by the incidence and severity of adverse events.
Results The apo B and LDL cholesterol were reduced by 19% to 54% and 21% to 52%, respectively, at doses of 100
mg/week mipomersen and higher in the 5-week treatment cohorts. Efficacy seemed to increase upon treatment
for 13 weeks at a dose of 200 mg/week. Injection site reactions (mild to moderate erythema [90%]) and he-
patic transaminase increases (17%) were the most common adverse events, leading to discontinuation in 2 sub-
jects and 1 subject, respectively. In the 13-week treatment cohort, 5 of 10 subjects (50%) had elevations 3
the upper limit of normal, 4 of which persisted on 2 consecutive occasions.
Conclusions Mipomersen might hold promise for treatment of patients not reaching target LDL cholesterol levels on stable statin
therapy. Further studies are needed to address the mechanisms and clinical relevance of transaminase changes after
mipomersen administration. (Dose-Escalating Safety Study in Subjects on Stable Statin Therapy;
NCT00231569) (J Am Coll Cardiol 2010;55:1611–8) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.069t
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ascular disease (1,2). This guideline is based upon the consis-
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009, accepted November 19, 2009.ent, positive association between circulating LDL cholesterol
evels and the incidence of major adverse cardiovascular events
bserved in large population studies (3,4), genetically deter-
ined hypercholesterolemia phenotypes (5,6), as well as major
linical outcome trials with statins (7–9). Results from the
atter investigations led to the recommendation for aggressive
eductions in LDL cholesterol, particularly in very-high-risk
atient populations (1). Despite the advent of potent statins
nd an increase in usage of combination therapies to support
hese updated guidelines, current therapies are still inadequate
or optimal treatment of a substantial portion of the high-risk
atient populations (10–12). Thus, there is a need for the
evelopment of therapeutic agents with complementary effects.
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Short-Term Mipomersen Treatment Added to Statins April 13, 2010:1611–8Mipomersen is a second-
generation antisense oligonucle-
otide designed to inhibit produc-
tion of human apolipoprotein
(apo) B-100 in the liver (13,14).
Apo B-100 is an essential com-
ponent of LDL cholesterol and
all other metabolically related
atherogenic lipoproteins. In
healthy human volunteers dosed
for 4 weeks, mipomersen pro-
duced dose-dependent reduction
in apo B levels that resulted in
reduction of LDL cholesterol
levels as much as 44% from base-
line (15). A drug elimination
half-life of approximately 30 days
resulted in a prolonged pharma-
cological effect. Treatment was
ell-tolerated and demonstrated an acceptable safety pro-
le. In a second Phase 1 study, concomitant administration
f either simvastatin or ezetimibe had no significant effect
n the pharmacokinetic properties of mipomersen and vice
ersa (16). These results are consistent with the metabolism
f mipomersen by nucleases followed by rapid clearance of
he metabolites via urinary excretion (17).
In this report we describe the results from a randomized,
lacebo-controlled, dose-escalation Phase 2 study designed to
etermine the efficacy and safety of mipomersen in hypercho-
esterolemic subjects receiving stable statin therapy.
ethods
tudy participants. Eligible participants were 18 to 65
ears of age without any clinically significant medical
ondition at screening and with fasting LDL cholesterol
etween 100 and 220 mg/dl on stable statin therapy.
articipants were receiving stable statin therapy at a dose of
40 mg/day for at least 3 months before treatment with the
tudy drug. The study was approved by the institutional
eview board of the local centers, and all subjects gave
ritten informed consent. The study was performed in
ompliance with the standards of Good Clinical Practice
ICH/E6/R1) and the Declaration of Helsinki (Washing-
on 2002).
Study participants enrolled sequentially into 1 of 5
-week dose-escalation cohorts at 4 sites in the Netherlands
etween October 24, 2005, and December 14, 2006. The
rotocol was amended on August 14, 2006, to evaluate the
ffects of an extended treatment period of 13 weeks in 2
ose cohorts, where eligible participants enrolled at 3 sites
n the Netherlands and 1 site in the U.S. between October
6, 2006, and March 5, 2007.
tudy design. This randomized, double-blind, placebo-
Abbreviations
and Acronyms
AE  adverse event
ALT  alanine
aminotransferase
Apo  apolipoprotein
LDL  low-density
lipoprotein
VLDL  very-low-density
lipoprotein
HDL  high-density
lipoprotein
TG  triglyceride
SAE  serious adverse
event
ULN  upper limit of
normalontrolled, dose-escalation study comprised 6 cohorts. Five mohorts were designed to evaluate the effects of short-term
reatment over a range of doses, and 1 was designed to
valuate an extended treatment period at the 200-mg dose
hat is under consideration for Phase 3. In the 5 dose-
scalation cohorts, the study drug was administered at a
ose of 30, 100, 200, 300, or 400 mg for a total of 7 doses
ver a 5-week period. In the extended treatment cohort, the
tudy drug was administered at a dose of 200 mg 3 times
qod) in the first week and then once/week for 12 weeks for
total of 15 doses.
Subjects were randomized at a ratio of 4:1 for active drug
o placebo by dose cohort. In the 5-week dose-escalation
ohorts, the study drug was administered by subcutaneous
njection on Days 1, 8, 10, 12, 15, 22, and 29. In the
3-week treatment cohort, the study drug was administered
y subcutaneous injection on Days 1, 3, 5, 8, 15, 22, 29, 36,
3, 50, 57, 64, 71, 78, and 85. A 2-month evaluation period
nvolving 4 visits followed the treatment period. After this
valuation period, subjects in the 5-week treatment cohorts
ith fasting LDL cholesterol 90% at baseline continued
ith monthly visits up to 24 weeks after the last dose.
ubjects in the 13-week treatment cohort continued with
onthly follow-up visits for an additional 4 months.
Safety end points included all adverse events (AEs) and
erious adverse events (SAEs); physical examination data
nd vital signs; and hepatic, renal, and coagulation profiles
rom laboratory tests. Laboratory evaluations included rou-
ine hematology, blood chemistries, and urinalysis.
Pre-specified efficacy end points included percentage
hange in LDL cholesterol and apo B from baseline on Day
9 (30 days after the last dose in the 5-week treatment
ohorts). Percentage change from baseline in very-low-
ensity lipoprotein (VLDL) cholesterol, high-density li-
oprotein (HDL) cholesterol, non-HDL cholesterol, total
holesterol, triglycerides (TGs), the LDL/HDL cholesterol
atio, and apo B/apo A1 ratio were also evaluated on Day
9. Post-hoc exploratory analysis of all lipid parameters
xcept for subclasses was performed on Day 99 for the
3-week cohort.
aboratory analysis. Fasting blood samples were analyzed
or apo B, apo A1, VLDL cholesterol, LDL cholesterol,
DL cholesterol, total cholesterol, and TGs. Samples from
he 5-week treatment cohorts were analyzed at Interlab
mbH (Munich, Germany), and those from the 13-week
reatment cohort were analyzed at Medpace (Cincinnati,
hio, and Belgium). In all cases, apo B and apo A1
oncentrations were determined by rate nephelometry; total
holesterol and TGs were measured by standard enzyme-
ased colorimetric assays. For the 5-week treatment co-
orts, VLDL cholesterol, LDL cholesterol, and HDL
holesterol concentrations were determined by gel electro-
horesis (Hydragel 30, Sebia Electrophoresis, Durham,
orth Carolina); and LDL cholesterol subclass concentra-
ions were determined by density gradient ultracentrifuga-
ion (Beckman Optima MAX-E, TLN-100 rotor, Beck-
an Coulter, Fullerton, California). For the 13-week
t
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April 13, 2010:1611–8 Short-Term Mipomersen Treatment Added to Statinsreatment cohort, VLDL and LDL cholesterol were calcu-
ated, and HDL cholesterol was determined by an enzyme-
ased colorimetric assay after dextran-sulfate precipitation.
Mipomersen plasma trough concentrations were mea-
ured at Pharma Bio-Research (Amsterdam, the Nether-
ands) with a hybridization-dependent enzyme-linked im-
unosorbent assay. Terminal plasma elimination half-lives
ere estimated by a non-compartmental method of analysis
WinNONLIN version 5).
tatistical analysis. Sample size was based upon an SD of
2% in the percentage change of LDL cholesterol and
nalysis of the data between 5 treatment groups and
ooled placebo. Under these assumptions a sample size of
/group would provide at least 80% power to detect a
0% difference in LDL cholesterol percentage change
ith a statistical significance level of 0.05. Study end
oints were analyzed on the intent-to-treat population,
hich consisted of all subjects that were randomized
n  74). Missing lipid parameter values were imputed
y the last observation carried forward method. Descrip-
ive statistics for apo B and LDL cholesterol data are
resented by dose versus time. Baseline was defined as the
verage of 2 screening values and the pre-dose Day 1
easurement. Percentage change from baseline for each
f the dose groups was compared with the pooled placebo
roup with the exact Wilcoxon rank sum test. Software
sed for the analyses was SAS version 8.2 (SAS Institute,
ary, North Carolina).
A visit window of7 days was applied for the analyses of
fficacy end points for the 5-week dose-escalation cohorts at
ay 59. Descriptive analysis of efficacy was performed on
Figure 1 Flow of Study Participants
*Liver function, fasting glucose, and bilirubin tests. †Statin therapy, age, blood pr
condition, and hepatitis C virus positive. AE  adverse event; F/U  follow-up; LDhe 13-week treatment cohort on Day 99 with a visit
indow of 4 days.
esults
tudy participants. One-hundred and thirty-two subjects
ere screened for inclusion in the study from October 2005
o February 2007 (Fig. 1). Seventy-four participants receiv-
ng stable statin therapy were randomly assigned sequen-
ially by dose cohort to either placebo or mipomersen
reatment. Demographic data and background statin ther-
py are summarized in Table 1 by treatment group.
Sixty-eight subjects completed the study protocol,
hereas in total 6 subjects were excluded in the course of the
tudy. In the 5-week dose-escalation cohorts, 3 subjects
ropped out: 1 was lost to follow-up, 1 missed 3 consecutive
isits, and 1 withdrew informed consent for personal rea-
ons. In the 13-week treatment cohort, 3 subjects (200
g/week) discontinued dosing due to an AE, comprising
ransient injection site reactions in 2 and a transient alanine
minotransferase (ALT) level increase 5 the upper limit
f normal (ULN) (maximum 213 U/l) occurring after
eceiving 9 doses in 1 (see section, Safety observations).
-week dose-escalation cohorts. The 5-week dose-
scalation cohorts involved 39 men and 23 women
anging in age from 49 to 65 years (data not shown).
aseline LDL cholesterol levels ranged from 84 to 216
g/dl with a mean of 135 mg/dl. Baseline lipid param-
ters are summarized in Table 2 by treatment group.
eductions in apo B and LDL cholesterol seemed to
ccur in a dose-dependent fashion in subjects treated
ith mipomersen on a background of stable statin ther-
, alcohol abuse, physical or medical
low-density lipoprotein cholesterol and/or triglycerides.essure
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Short-Term Mipomersen Treatment Added to Statins April 13, 2010:1611–8py (Fig. 2). Percentage changes in apo B and LDL
holesterol levels from baseline were statistically signifi-
ant relative to placebo on Day 59 (30 days after the
-week treatment period) in the 100-mg/week and
igher dose groups (Table 3). The maximum reduction in
po B and LDL cholesterol was observed in the 300-mg/
eek dose group, with reductions of 54% and 52% from
aseline, respectively (p  0.001 for both). In line, a
aximum reduction of 52% from baseline in non-HDL
holesterol levels (p  0.001) was demonstrated in the
00-mg/week dose group. Dose-dependent effects on apo
/A1 and LDL/HDL cholesterol ratios were consistent
ith the decreases in apo B and LDL cholesterol.
reatment at doses of 300 mg/week and 400 mg/week
lso produced a significant reduction in TGs of 41% (p 
.05) and 31% (p  0.01) from baseline. The HDL
holesterol levels were unaffected across all dose cohorts.
Seventy-three percent of the subjects in the 200-mg/
eek or higher dose cohorts (24 of 33) had LDL
emographic Data and Background Statin TherapyTable 1 Demographic Data and Background Statin Therapy
5-Week Tr
Placebo
(n  15)
30 mg/week
(n  8)
100 mg/week
(n  8)
200
(n
Sex (M:F) 8:7 6:2 4:4
Age (yrs) 60.8 3.3 58.0 3.9 57.4 4.1 58.
Statin (mg/day)
Atorvastatin
10 0 (0) 0 (0) 1 (13) 2
20 6 (40) 2 (25) 2 (25) 6
40 1 (7) 0 (0) 2 (25) 3
Simvastatin
5 0 (0) 0 (0) 1 (13) 0
10 3 (20) 0 (0) 1 (13) 3
20 2 (13) 1 (13) 1 (13) 2
40 2 (13) 5 (63) 0 (0) 0
Rosuvastatin
10 1 (7) 0 (0) 0 (0) 0
tatin values represent n (%) by statin type and dose. Median duration of statin therapy before do
aseline Lipid Parameters Among 5-Week Treatment CohortsTable 2 Baseline Lipid Parameters Among 5-Week Treatment C
Lipid Parameters
(mg/dl)
Placebo
(n  13)*
30 mg/week
(n  8)*
100 mg/wee
(n  8)
Apo B 105.0 17.0 97.9 10.8 106.0 24.3
LDL cholesterol 130.4 19.9 114.9 18.7 135.0 34.4
VLDL cholesterol 13.1 6.8 13.3 6.5 11.8 7.7
Non-HDL cholesterol 143.5 23.5 128.1 16.7 146.8 36.9
HDL cholesterol 65.3 20.9 54.0 8.6 51.5 7.7
Total cholesterol 208.8 21.7 182.1 23.8 198.3 37.5
Triglycerides 133 (93–249) 118 (76–188) 117 (85–237
Apo B/A1 0.6 0.2 0.6 0.0 0.7 0.2
LDL/HDL cholesterol 2.2 0.7 2.1 0.2 2.7 0.9
alues represent the mean SD. Triglycerides are presented as the median and range (minimum
mmol/l). *Baseline lipid values for 1 subject were based on the average of 4 independent measur
ose as described in the Methods section.
Apo apolipoprotein; HDL high-density lipoprotein; LDL low-density lipoprotein; VLDL very-low-dholesterol levels below 100 mg/dl after 5 weeks of
reatment (Table 4). Thirty-three percent had LDL
holesterol levels below 70 mg/dl. All but 1 of the 24
ubjects with LDL cholesterol levels below 100 mg/dl
lso achieved non-HDL cholesterol levels below 130
g/dl and apo B levels below 90 mg/dl. No relationship
etween baseline LDL cholesterol in percentage change
fter mipomersen therapy was observed.
3-week treatment cohort. The 13-week treatment cohort
nvolved 12 subjects (7 men and 5 women) ranging in age
rom 50 to 65 years. Baseline LDL cholesterol levels
anged from 104 to 154 mg/dl with a mean of 127 mg/dl
data not shown). Ten subjects were assigned to active
reatment. An incremental reduction in apo B and LDL
holesterol of 36% from baseline was demonstrated in
ubjects treated with 200 mg/week mipomersen, 2 weeks
fter the last dose of the treatment period (Table 5).
hese reductions were greater than that observed in the
ame-dose 5-week treatment group. The HDL choles-
nt Cohorts
13-Week
Treatment
Cohort
eek
)
300 mg/week
(n  8)
400 mg/week
(n  9)
200 mg/week
(n  10)
Total
(n  74)
4:4 7:2 6:4 46:28
8 56.9 4.3 61.4 3.2 59.0 4.0 59.0 4.1
2 (25) 1 (11) 2 (20) 8 (11)
2 (25) 2 (22) 0 (0) 20 (27)
0 (0) 1 (11) 3 (30) 10 (14)
0 (0) 0 (0) 0 (0) 1 (1)
1 (13) 2 (22) 1 (10) 11 (15)
1 (13) 2 (22) 2 (20) 11 (15)
2 (25) 1 (11) 2 (20) 12 (16)
0 (0) 0 (0) 0 (0) 1 (1)
timated as 4 years.
ts
200 mg/week
(n  16)
300 mg/week
(n  8)
400 mg/week
(n  9)
Total
(n  62)
103.7 17.7 138.8 14.4 109.1 13.0 108.8 20.2
128.5 20.2 170.9 26.5 136.3 18.6 134.6 26.8
13.8 12.6 16.4 8.3 11.6 5.3 13.3 8.6
142.3 28.7 187.3 28.2 147.9 20.3 147.9 30.2
69.0 21.5 64.1 18.3 58.7 11.7 61.9 17.6
211.3 33.5 251.5 35.8 206.6 21.9 209.8 33.9
132 (65–301) 152 (128–210) 114 (70–209) 134 (65–301)
0.6 0.2 0.8 0.2 1.4 2.2 0.8 0.8
2.1 0.8 2.9 0.9 2.4 0.7 2.4 0.8
mum). Multiply values by 0.0259 (cholesterol) and 0.0113 (triglycerides) for conversion to SI units
re the first dose; all others were based on the average of 3 independent measures before the firsteatme
mg/w
 16
11:5
3 3.
(13)
(38)
(19)
(0)
(19)
(13)
(0)
(0)ohor
k
)
to maxi
es befoensity lipoprotein.
EV
o
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April 13, 2010:1611–8 Short-Term Mipomersen Treatment Added to StatinsFigure 2 Dose-Dependent and Prolonged Effect of Mipomersen on Apo B and LDL Cholesterol in 5-Week Treatment Cohorts
(A) Apolipoprotein (Apo) B and (B) low-density lipoprotein (LDL) cholesterol presented as mean percentage change from baseline (BLSN)  SEM. Time period ranges
from Day 1 to Day 87 (end of evaluation period). Grey-shading indicates treatment period, and solid circles located above the x-axes indicate the dose schedule
(7 doses). Unshaded area indicates the post-treatment follow-up period.ffects on Lipid Parameters Among 5-Week Treatment CohortsTable 3 Effects on Lipid Parameters Among 5-Week Treatment Cohorts
Percentage Change From Baseline
Lipid Parameters
(mg/dl)
Placebo
(n  13)
30 mg/week
(n  8)
100 mg/week
(n  8)
200 mg/week
(n  16)
300 mg/week
(n  8)
400 mg/week
(n  9)
Apo B 1.8 16.3 0.4 11.6 19.0 10.6* 24.4 19.7† 54.4 19.2‡ 44.0 21.5‡
LDL cholesterol 3.3 12.8 2.3 11.9 21.2 10.1† 27.4 20.7‡ 51.8 14.3‡ 37.5 30.5*
VLDL cholesterol 1.0 38.0 3.7 41.7 5.6 33.9 3.0 84.6 27.4 87.5 45.8 40.5†
Non-HDL cholesterol 3.3 12.4 3.2 12.0 19.4 9.8† 25.0 23.4† 52.0 14.9‡ 38.4 30.6*
HDL cholesterol 8.0 13.6 1.9 12.5 2.8 11.3* 2.8 13.5 2.9 17.3 1.4 24.7
Total cholesterol 0.0 9.3 2.7 10.8 15.0 8.3† 15.4 17.7† 38.5 12.5‡ 28.4 16.1‡
Triglycerides 1.0 3.5 3.9 23.1 40.5* 30.8†
Apo B/A1 241 883 1.0 7.4 16.5 11.2* 24.1 19.1† 55.6 14.2‡ 42.7 30.2†
LDL/HDL cholesterol 9.7 15.8 0.7 13.3 19.2 11.8 29.7 17.8† 53.7 11.0‡ 19.5 84.0*
alues represent the mean SD, 30 days after the last dose in the 5-week treatment cohorts (Day 59). Triglycerides are presented as the median. Percentage change from baseline (3 time points) for each
f the dose groups was compared with the pooled placebo group. The p value was calculated with the exact Wilcoxon rank sum test. *p  0.05; †p  0.01; ‡p  0.001.
Abbreviations as in Table 2.
t
e
s
c
p
S
O
t
r
p
m
5
r
p
p
s
t
n
s
r
w
s
f
t
m
n
p
s

l
s
e
t
a
r
a
w
e
E
B
n
1616 Akdim et al. JACC Vol. 55, No. 15, 2010
Short-Term Mipomersen Treatment Added to Statins April 13, 2010:1611–8erol levels remained unchanged. A plasma terminal
limination half-life of approximately 30 days was ob-
erved across all dose groups. There was no significant
hange in the drug’s half-life with extension of the dosing
eriod from 5 to 13 weeks.
afety observations. Three SAEs occurred in this study.
ne subject presented with fever (39°C) that occurred more
han 12 h after receiving a first dose of 400 mg. The fever
esolved spontaneously within 24 h and was considered
ossibly related to the study drug. The second SAE was a
yocardial infarction that occurred 6 weeks after the
-week treatment period. In view of the severe atheroscle-
otic disease on coronary angiography in this high-risk
atient (hypercholesterolemia, obesity, smoking with 48
ack-years), this AE was considered as “unknown relation-
hip to the study drug.” The third SAE was for surgical
reatment of lumbar spinal stenosis, which was considered
ot related to the study drug.
The most common AE in this study was a reaction at the
ubcutaneous injection site (Table 6). These injection site
ffects on Lipid and Lipoprotein Concentrations Among 5-Week TreTable 4 Effects on Lipid and Lipoprotein Concentrations Among
Lipid Parameter
Placebo
(n  13)
30 mg/week
(n  8)
10
LDL cholesterol
Baseline 130.4 19.9 114.9 18.7 1
Day 59 126.4 26.8 117.3 22.4 1
n (%) 100 mg/dl 4 (31) 2 (25)
n (%) 70 mg/dl 0 (0) 0 (0)
Non-HDL cholesterol
Baseline 143.5 23.5 128.1 16.7 1
Day 59 139.3 31.2 131.5 18.4 1
n (%) 130 mg/dl 5 (38) 5 (63)
Apo B
Baseline 105.0 17.0 97.9 10.8 1
Day 59 102.7 22.2 97.2 13.2
n (%) 90 mg/dl 4 (31) 2 (25)
aseline and Day 59 values represent the mean  SD in mg/dl. The number of subjects (n) below
umber of subjects in the group at baseline (%) is in parenthesis.
Abbreviations as in Table 2.
Effects on Lipid Parameters After 13 Weeks ofTable 5 Effects on Lipid Parameters After 1
Lipid Parameter (mg/dl)
Baseline
(n  10)
Apo B 109.0 12.0
LDL cholesterol 126.9 15.1
VLDL cholesterol 27.4 7.9
Non-HDL cholesterol 155.6 15.4
HDL cholesterol 46.9 16.0
Total cholesterol 202.5 18.9
Triglycerides 145
Apo B/A1 0.8 0.2
LDL/HDL cholesterol 2.9 0.9
Values represent the mean SD. Triglycerides are presented as the m
conversion to SI units (mmol/l).
Abbreviations as in Table 2.eactions were characterized by mild-to-moderate erythema,
hich did not worsen with repeated dosing and resolved
pontaneously several days after the injection. Another
requent AE was transaminase increases. In the 5-week
reatment cohorts, 5 of the 49 subjects (10%) receiving
ipomersen (n  2, 200 mg/week; n  2, 300 mg/week;
 1, 400 mg/week) and 1 of 13 subjects (8%) receiving
lacebo experienced ALT elevations 3 ULN. In 3
ubjects (n  1, 200 mg/week; n  2, 300 mg/week) ALT
3 ULN persisted on 2 or more consecutive occasions at
east 7 days apart. In the 13-week treatment cohort, 5 of 10
ubjects (50%) had elevations 3 ULN, of which 4 had
levations 3 ULN on 2 consecutive occasions. None of
he patients showed elevations in total bilirubin2 ULN,
nd other measures of liver function, such as albumin,
emained unchanged.
Other AEs that demonstrated a possible dose-dependent
ssociation were flu-like illness, fatigue, and pyrexia. There
as no evidence of abnormal changes or treatment-related
ffects on kidney function on the basis of serum chemistry
nt Cohortseek Treatment Cohorts
Mean Values at Baseline and Day 59
/week
8)
200 mg/week
(n  16)
300 mg/week
(n  8)
400 mg/week
(n  9)
34.4 128.5 20.2 170.9 26.5 136.3 18.6
32.4 91.6 23.5 84.0 36.1 86.6 47.1
0) 10 (63) 7 (88) 7 (78)
3) 3 (19) 3 (38) 5 (56)
36.9 142.3 28.7 187.3 28.2 147.9 20.3
33.9 104.3 30.6 91.1 37.9 91.9 48.7
5) 12 (75) 7 (88) 7 (78)
24.3 103.7 17.7 138.8 14.4 109.1 13.0
27.5 77.1 19.7 64.7 32.4 61.8 26.6
3) 11 (69) 7 (88) 7 (78)
icated target level at the end point is presented by dose group, where the percentage of the total
g at 200 mg/Week Mipomerseneks of Dosing at 200 mg/Week Mipomersen
y 99
 10)
Change
Absolute %
 20.3 38.2 14.2 35.7 14.1
 23.8 45.6 23.5 35.8 16.4
 13.3 2.0 7.2 11.0 21.6
 32.3 43.8 27.5 28.5 17.5
 19.1 0.1 4.3 1.1 8.5
 31.9 43.7 26.1 21.8 12.9
27 19.7 14.6
 0.2 0.2 0.1 31.1 12.6
 0.8 1.0 0.6 35.7 17.5
Multiply values by 0.0259 (cholesterol) and 0.0113 (triglycerides) foratme5-W
0 mg
(n 
35.0
06.7
4 (5
1 (1
46.8
18.6
6 (7
06.0
86.9
5 (6
the indDosin3 We
Da
(n
70.8
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25.4
111.8
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158.8
1
0.5
1.9
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ffects of treatment on coagulation on the basis of pro-
hrombin and activated partial thromboplastin times.
iscussion
n the present study, mipomersen produced significant
ncremental lipid-lowering effects in hypercholesterolemic
ubjects receiving stable statin therapy, resulting in an
ncreased proportion of patients reaching LDL-target lev-
ls. A substantial number of patients, however, experienced
ransient increases in hepatic transaminase levels, particu-
arly at higher dosages of mipomersen, without bilirubin
hange or change in other liver synthesis functions. Before
ong-term application of higher-dosed mipomersen, addi-
ional studies are needed to elucidate the mechanism as well
s the clinical relevance of these transaminase increases.
fficacy. Mipomersen seemed to reduce apo B and LDL
holesterol levels from the on-statin baseline in a dose-
ependent fashion. However, because steady state levels for
fficacy are calculated to be reached only at 26 weeks, it is
ifficult to draw conclusions on dose-dependent efficacy in
he present 5-week study. Reductions in LDL cholesterol
anged from 18% to 49% relative to the placebo-control
roup at doses of 100 mg or higher. This response com-
ares favorably to those reported for other lipid-lowering
gents, (e.g., ezetimibe [18] and colesevelam [19]) when
dded to stable doses of statins in subjects with primary
ypercholesterolemia.
In the current study population, mipomersen produced
road atherogenic lipid-lowering effects that were consistent
ith earlier phase 1 studies involving healthy volunteers
14,15). These effects included significant reductions in
on-HDL cholesterol and TGs. Non-HDL cholesterol is
onsidered a secondary target of therapy after LDL choles-
erol, particularly when TGs are above 200 mg/dl (1).
levated TG concentrations are typically associated with
ardiovascular risk (20,21) and the presence of highly
therogenic, small-dense LDL particles (22). Reductions in
reatment-Emergent Adverse Events by Dose Group (Mipomersen TTable 6 Treatment-Emergent Adverse Events by Dose Group (M
Trea
Event, n (%)
Placebo
(n  15)
30 mg/week
(n  8)
100 mg/week
(n  8)
200
Injection site reaction 2 (13) 6 (75) 8 (100)
Headache 6 (40) 2 (25) 2 (25)
Influenza-like illness 1 (7) 1 (13) 2 (25)
Fatigue 0 (0) 0 (0) 0 (0)
Nasopharyngitis 1 (7) 1 (13) 2 (25)
Back pain 1 (7) 1 (13) 2 (25)
Hepatic enzyme increase 1 (7) 0 (0) 0 (0)
Urinary tract infection 0 (0) 2 (25) 3 (38)
Pyrexia 0 (0) 0 (0) 0 (0)
alue (n) denotes the number of subjects with at least 1 event. Percentage of the total number ohese secondary parameters by mipomersen were within wange to those reported for other agents, (e.g., ezetimibe
18] and fibrates [23]) when added to ongoing statin
herapy. The HDL cholesterol levels were not significantly
ltered during mipomersen administration.
afety. Three SAEs occurred in this study, of which 2
myocardial infarction and lumbar stenosis) were deemed
ot related to the study drug by the investigator. The
emaining SAE (fever) occurred subsequent to administra-
ion of the first 400-mg dose and was considered possibly
elated to the study drug. In fact, a transient temperature
ncrease was experienced by 2 other subjects in this dose
roup subsequent to the first dose but with no recurrence
pon continued treatment. Flu-like symptoms in general
eemed to be dose-related and might have reflected a
ransient response upon initial exposure to a higher concen-
ration of the drug (24).
Hepatic enzyme increases were observed in a substantial
roportion of subjects, particularly in the higher dose
ohorts, but without concomitant changes in other indica-
ors of hepatic injury (e.g., increase in total bilirubin or
ecrease in albumin). The basis and clinical significance of
he transaminase increases is not known at the present time.
n the basis of the pharmacology, it is conceivable that
hanges in transaminase levels might reflect a change in
epatic TG accumulation. In line, inhibition of a more
istal enzyme involved in apo B lipidation—the microsomal
G transfer protein—has also been associated with hepatic
G accumulation in both animal models (25,26) as well as
n humans (27). In contrast, studies in both mouse and
onkey models of hyperlipidemia found no evidence of
ersistent liver TG accumulation from antisense inhibition
f apo B (13,14). The latter coincided with compensatory
hanges in response to antisense inhibition of apo B leading
o increased fatty acid oxidation and decreased fatty acid
ynthase activity, which did not occur after microsomal TG
ransfer protein inhibition in these same animal models
14). To directly assess the impact of apo B inhibition on
epatic TG excretion, a placebo-controlled study is under-
d >10%)ersen Treated >10%)
ek
Cohorts
13-Week
Treatment Cohort
week
6)
300 mg/week
(n  8)
400 mg/week
(n  9)
200 mg/week
(n  10)
Mipomersen
(n  59)
) 8 (100) 8 (89) 9 (90) 53 (90)
) 3 (38) 3 (33) 2 (20) 18 (31)
2 (25) 4 (44) 5 (50) 15 (25)
) 1 (13) 4 (44) 4 (40) 11 (19)
) 2 (25) 1 (11) 2 (20) 10 (17)
0 (0) 3 (33) 3 (30) 10 (17)
2 (25) 2 (22) 5 (50) 10 (17)
0 (0) 0 (0) 0 (0) 6 (10)
) 0 (0) 3 (33) 1 (10) 6 (10)
ts (%) by treatment group is in parenthesis.reateipom
5-We
tment
mg/
(n  1
14 (88
6 (38
1 (6)
2 (13
2 (13
1 (6)
1 (6)
1 (6)
2 (13ay to elucidate the effects of mipomersen treatment on
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yperlipidemia.
linical implications. Results from the current Phase 2
tudy bear direct relevance to the treatment of patients at
igh risk for cardiovascular disease. In fact, mipomersen
n top of statin therapy resulted in a significant, higher
roportion of patients reaching target LDL (100 mg/dl)
s well as intensive LDL target (70 mg/dl) compared with
tatin monotherapy. However, only a minority of patients
sed maximally tolerated lipid-lowering therapy in the
resent study. Because mipomersen is likely to be used in
atients not reaching target levels despite maximum con-
entional therapy, further studies are needed to address the
ffects of mipomersen when given on top of high-dose statin
uch as atorvastatin 80 mg or rosuvastatin 20 to 40 mg.
iven the short-term treatment period, small sample size,
nd narrowly defined subject population, additional clinical
tudies are required to confirm these results. Ongoing and
lanned clinical studies for mipomersen include longer-term
osing for 6 to 24 months in unmet medical need popula-
ions (e.g., those with familial hypercholesterolemia), those
ith high-risk cardiovascular disease that are not reaching
heir goal on current therapies, and those intolerant to statin
herapy.
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